Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
13 août 2024 17h37 HE
|
Calidi Biotherapeutics, Inc
Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the appointment...
Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor
29 juil. 2024 09h00 HE
|
Calidi Biotherapeutics, Inc
SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform
18 juil. 2024 08h00 HE
|
Calidi Biotherapeutics, Inc
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
16 juil. 2024 08h00 HE
|
Calidi Biotherapeutics, Inc
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
Oncolytic Virus Therapy Market Size Clinical Trials Sales Forecast 2030
14 mai 2024 01h08 HE
|
KuicK Research
Delhi, May 14, 2024 (GLOBE NEWSWIRE) -- Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030 Report Highlights: Global Oncolytic Virus Immunotherapy Therapy...
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
09 avr. 2024 12h00 HE
|
Imugene Limited
Imugene announced poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the AACR Conference.
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
26 oct. 2023 09h00 HE
|
Mustang Bio, Inc.
MB‐101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) are separately well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials; preclinical data...
Global Oncolytic Virus Therapies Market Size to Reach USD 1,546.51 Million in 2032 | Emergen Research
23 oct. 2023 09h00 HE
|
Emergen Research
Vancouver, Oct. 23, 2023 (GLOBE NEWSWIRE) -- The global oncolytic virus therapies market size is expected to reach USD 1,546.51 Million at a steady CAGR of 26.2% in 2032, according to latest...
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
07 sept. 2023 16h01 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President,...
Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology
10 juil. 2023 07h00 HE
|
Genelux Corporation
Phase 1 trial conducted at Memorial Sloan Kettering Cancer Center, New York, investigated the safety, feasibility and immune activating effects of Olvi-Vec by intrapleural administration. Documented...